128056-99-5

Basic information

• Product Name: (2R,3S)-1,2-O-isopropylidene-3-O-(p-toluenesulfonyl)-1,2,3,4-butanetetrol
• Synonyms: (2R,3S)-1,2-O-isopropylidene-3-O-(p-toluenesulfonyl)-1,2,3,4-butanetetrol
• CAS NO: 128056-99-5
• Molecular Weight: 316.375
• Mol File: 128056-99-5.mol

Chemical Properties

• CAS DataBase Reference: (2R,3S)-1,2-O-isopropylidene-3-O-(p-toluenesulfonyl)-1,2,3,4-butanetetrol(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S)-1,2-O-isopropylidene-3-O-(p-toluenesulfonyl)-1,2,3,4-butanetetrol(128056-99-5)
• EPA Substance Registry System: (2R,3S)-1,2-O-isopropylidene-3-O-(p-toluenesulfonyl)-1,2,3,4-butanetetrol(128056-99-5)

Safety Data

• Hazardous Substances Data: 128056-99-5(Hazardous Substances Data)

Upstream product

• 126946-54-1 ethyl (2R,3R)-3,4-O-isopropylidene-2-p-toluenesulfonyl-3,4-dihydroxybutanoate 
• 92973-39-2 O³,O⁴-(1-methylethylidene)-L-threonic acid 
• 92973-40-5 methyl (2R,3S)-3,4-O-isopropylidene-2,3,4-trihydroxybutanoate 
• 166249-17-8 methyl (2R,3S)-3,4-O-isopropylidene-2,3,4-trihydroxy-2-O-(p-toluenesulfonyl)butanoate 
• 126946-53-0 ethyl (2R,3S)-3,4-O-isopropylidene-2-p-toluenesulfonyl-3,4-dihydroxybutanoate 
• 1379602-81-9 (2R)-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl](hydroxy)ethanoic acid sodium salt 
• 15042-01-0 5,6-O-isopropylidene-L-ascorbic acid 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1418112-79-4 4-chloro-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzylthio)pyrimidine 
• 1418112-80-7 N-(6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzyl-thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide 
• 128111-95-5 (2R,3R)-2-<2-O-benzyl-3,4-O-isopropylidene-2,3,4-trihydroxybut-1-yl>-1,3-dithiane 
• 128057-00-1 (3R,4R)-3-O-benzyl-4,5-O-isopropylidene-3,4,5-trihydroxypentanal 
• 74134-79-5 (4R)-2,2-dimethyl-4-[(2R)-oxiran-2-yl]-1,3-dioxolane 
• 128112-01-6 (2R,3S)-2-<2-O-benzyl-3,4-O-isopropylidene-2,3,4-trihydroxybut-1-yl>-1,3-dithiane 
• 128057-04-5 (3R,4S)-3-O-benzyl-4,5-O-isopropylidene-3,4,5-trihydroxypentanal 
• 74134-78-4 (2S,3R)-3,4-epoxy-1,2-O-isopropylidenebutane-1,2-diol 

Relevant articles and documents

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE

There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

From L-ascorbic acid to protease inhibitors: Practical synthesis of key chiral epoxide intermediates for aspartyl proteases

Efficient synthetic routes were developed to prepare a sizable amount (4-15 grams) of the chiral epoxides 4-6 as versatile intermediates for the synthesis of aspartyl protease inhibitors of therapeutic interest such as HIV protease and β-secretase. Oxidative cleavage of the C(2)-C(3) double bond of L-ascorbic acid followed by functional group manipulation led to the preparation of the epoxide 10, which was opened with an azide to yield a common aziridine intermediate 12. Through opening of the aziridine ring of 12 with either a carbon or a sulfur nucleophile, chiral epoxide precursors 4-6 could be prepared for various HIV protease inhibitors. Except for the final low melting epoxides 5 and 6, all intermediates were obtained as crystalline solids, thus the synthetic pathway can be easily applied to a large-scale synthesis of the chiral epoxides.

Synthesis of enantiomeric 9-(2′,3′,4′-trihydroxybutyl)adenine derivatives from L-ascorbic and D-isoascorbic acids

L-Ascorbic and D-isoascorbic acids were employed in syntheses of 9-(2′,3′,4′-trihydroxybutyl)adenines protected at 3′ and 4′ oxygens (all four enantiomers) and at 2′ oxygen (2′S,3′R and 2′S,3′S enantiomers).

Chemistry of L-Ascorbic and D-Isoascorbic Acids. An Efficient Synthesis of 2-Deoxypentofuranoses

L-Ascorbic and D-isoascorbic acids have been converted to methyl 3-O-benzyl-2-deoxypentofuranosides.The synthetic routes are enantiospecific, efficient, and economic and proceed in high yields.